


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:50:21Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406851" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406851</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>bmjo</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Open</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id><journal-id journal-id-type="pmc-domain-id">1609</journal-id><journal-id journal-id-type="pmc-domain">bmjo</journal-id><journal-id journal-id-type="publisher-id">bmjopen</journal-id><journal-title-group><journal-title>BMJ Open</journal-title></journal-title-group><issn pub-type="epub">2044-6055</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406851</article-id><article-id pub-id-type="pmcid-ver">PMC12406851.1</article-id><article-id pub-id-type="pmcaid">12406851</article-id><article-id pub-id-type="pmcaiid">12406851</article-id><article-id pub-id-type="pmid">40887111</article-id><article-id pub-id-type="doi">10.1136/bmjopen-2024-098446</article-id><article-id pub-id-type="publisher-id">bmjopen-2024-098446</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Protocol</subject></subj-group><subj-group subj-group-type="heading"><subject>Cardiovascular Medicine</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1683</subject><subject>1506</subject></subj-group></article-categories><title-group><article-title>Screening for endocrine hypertension in China: protocol for a multicentre prospective cohort study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-8262-2236</contrib-id><name name-style="western"><surname>Zhou</surname><given-names initials="Z">Zhanyang</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yin</surname><given-names initials="Z">Zheng</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3986-1804</contrib-id><name name-style="western"><surname>Miao</surname><given-names initials="H">Huanhuan</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="S">Shijie</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhang</surname><given-names initials="Y">Yuqing</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><collab>Screening for Endocrine Hypertension in China (SEHIC) Study<contrib-group><contrib contrib-type="collab"><name name-style="western"><surname>Wang</surname><given-names initials="X">Xingyu</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Cheng</surname><given-names initials="W">Wenli</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Zhu</surname><given-names initials="Y">Yuchun</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Qian</surname><given-names initials="J">Jun</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Xia</surname><given-names initials="C">Chengjing</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Zhang</surname><given-names initials="T">Tong</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Li</surname><given-names initials="H">Heng</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Zeng</surname><given-names initials="C">Chunping</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Huang</surname><given-names initials="Z">Zhihua</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Chen</surname><given-names initials="Y">Yequn</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Chen</surname><given-names initials="S">Songzhang</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Chen</surname><given-names initials="W">Weini</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Shen</surname><given-names initials="Y">Yang</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Chen</surname><given-names initials="K">Kang</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Yu</surname><given-names initials="S">Shenglong</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Xu</surname><given-names initials="G">Guanxue</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Li</surname><given-names initials="J">Jilin</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Ma</surname><given-names initials="Y">Yujing</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Ma</surname><given-names initials="S">Sha</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Xu</surname><given-names initials="H">Hongxin</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Zhu</surname><given-names initials="C">Congfei</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Gu</surname><given-names initials="N">Ning</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Wang</surname><given-names initials="C">Chen</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Guo</surname><given-names initials="S">Shouyu</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Yu</surname><given-names initials="Q">Qin</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Chen</surname><given-names initials="Q">Qian</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Jiang</surname><given-names initials="X">Xiaolei</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Li</surname><given-names initials="G">Gang</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Yu</surname><given-names initials="Z">Zongze</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Lan</surname><given-names initials="J">Jianhua</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Fu</surname><given-names initials="G">Guangqing</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Zhu</surname><given-names initials="D">Dan</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Bai</surname><given-names initials="B">Bing</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>He</surname><given-names initials="B">Bingxun</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Zhou</surname><given-names initials="D">Dong</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yong</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yong</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Tang</surname><given-names initials="C">Chengwu</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Yang</surname><given-names initials="J">Jie</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Wang</surname><given-names initials="M">Miaoyun</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Mei</surname><given-names initials="L">Linse</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Wu</surname><given-names initials="Q">Qi</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Qian</surname><given-names initials="C">Caizhen</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Li</surname><given-names initials="Y">Yong</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Zhou</surname><given-names initials="X">Xinhong</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Ye</surname><given-names initials="S">Shiwei</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Yuan</surname><given-names initials="H">Hong</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Ji</surname><given-names initials="X">Xiaojun</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Wu</surname><given-names initials="Y">Yingang</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Wu</surname><given-names initials="X">Xiaofeng</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Teng</surname><given-names initials="Y">Yiming</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Hu</surname><given-names initials="B">Bin</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Ai</surname><given-names initials="Z">Zongyao</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Chen</surname><given-names initials="F">Fujian</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Lv</surname><given-names initials="H">Hao</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Fei</surname><given-names initials="Y">Yang</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Chen</surname><given-names initials="X">Xiaoshu</given-names></name></contrib><contrib contrib-type="collab"><name name-style="western"><surname>Hu</surname><given-names initials="Y">Yu</given-names></name></contrib></contrib-group></collab></contrib><aff id="aff1"><label>1</label><institution>Heart Failure Center, Fuwai Hospital, Chinese Academy of Medical Sciences</institution>, <addr-line content-type="city">Beijing</addr-line>, <country>China</country></aff><aff id="aff2"><label>2</label><institution>Beijing Anzhen Hospital Affiliated to Capital Medical University</institution>, <addr-line content-type="city">Beijing</addr-line>, <country>China</country></aff></contrib-group><author-notes><fn><p>Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p></fn><fn fn-type="COI-statement" id="fn5"><p>None declared.</p></fn><corresp id="cor1">Dr Yuqing Zhang; <email xlink:href="yqzhang9988@163.com">yqzhang9988@163.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>31</day><month>8</month><year>2025</year></pub-date><volume>15</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">494363</issue-id><elocation-id>e098446</elocation-id><history><date date-type="received"><day>24</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>07</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:&#160;<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="bmjopen-15-8.pdf"/><self-uri xlink:title="pdf" xlink:href="bmjopen-15-8.pdf"/><abstract><title>Abstract</title><sec><title>Introduction</title><p>Secondary hypertension accounts for 5%&#8211;10% of all hypertensive patients. Among these conditions, endocrine hypertension, such as primary aldosteronism (PA), Cushing&#8217;s syndrome (CS) and pheochromocytoma and paraganglioma (PPGL), is a common and significantly harmful cause. With advancements in diagnostic techniques, the prevalence of endocrine hypertension is much higher than previously reported, but large-scale epidemiological survey data in this field are still lacking in China.</p></sec><sec><title>Methods and analysis</title><p>This is a multicentre prospective cohort study to investigate the epidemiological characteristics of endocrine hypertension, such as PA, PPGL and CS, in the Chinese hypertensive population. Standardised clinical assessments, biochemical tests and mass spectrometry-based screening will be performed to identify endocrine hypertension caused by PA, PPGL and CS. The primary outcome is the prevalence and characteristics of endocrine hypertension. Secondary outcomes include establishing standardised detection methods. Participants will be followed for at least 1 year.</p></sec><sec><title>Ethics and dissemination</title><p>The protocol was approved by the Medical Ethics Committee of Beijing Children&#8217;s Hospital ((2023)-E-028-Y), the coordinating site and all participating centres. Results will be published in a peer-reviewed journal and presented at scientific meetings.</p></sec><sec><title>Trial registration number</title><p>ChiCTR2300075747.</p></sec><sec><title>Protocol version</title><p>Version 7 (23 June 2022).</p></sec></abstract><kwd-group><kwd>Hypertension</kwd><kwd>Adrenal disorders</kwd><kwd>Blood Pressure</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Development Center for Medical Science &amp; Technology National Health</institution></institution-wrap></funding-source></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Zhejiang Biozon Medical Technology Co., Ltd</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>STRENGTHS AND LIMITATIONS OF THIS STUDY</title></caption><list list-type="bullet" list-content="ul"><list-item><p>Mass spectrometry is used as a standardised, high-specificity method to detect hormone profiles across sites.</p></list-item><list-item><p>The protocol includes uniform case definitions, quality control procedures and centralised data management.</p></list-item><list-item><p>Subgroup analyses are planned for newly diagnosed, resistant and high-normal blood pressure populations.</p></list-item><list-item><p>Confirmatory testing is limited to participants with positive initial screening results, which may bias performance estimates.</p></list-item></list></boxed-text><sec sec-type="intro" id="s1"><title>Introduction</title><p> Hypertension is a major public health problem that is responsible for a wide range of clinical, economic and societal issues.<xref rid="R1" ref-type="bibr"><sup>1 2</sup></xref> Hypertension can be divided into primary and secondary forms. Secondary hypertension is hypertension due to an identifiable cause that may be treatable with an intervention specific to the cause, accounting for 5%&#8211;10% of hypertension cases.<xref rid="R3" ref-type="bibr"><sup>3</sup></xref> Endocrine-related hypertension, such as primary aldosteronism (PA), pheochromocytoma (PCC) and paraganglioma (PGL) and Cushing&#8217;s syndrome (CS), is a common and significant cause of secondary hypertension identified through screening.</p><p>With the development of screening techniques, the prevalence of PA has been recognised to be underestimated. In particular, the implementation of aldosterone to renin ratio testing in outpatient settings significantly increases the detection rate of PAs, facilitating early diagnosis and treatment.<xref rid="R4" ref-type="bibr">4</xref><xref rid="R6" ref-type="bibr">6</xref> PA accounts for approximately 5%&#8211;10% or more of the hypertensive population.<xref rid="R7" ref-type="bibr">7</xref><xref rid="R9" ref-type="bibr">9</xref> Currently, large-scale epidemiological surveys on PA are lacking in China, even with the most conservative estimates, at least 12.25&#8201;million out of the 245&#8201;million people with hypertension may have PA.<xref rid="R10" ref-type="bibr"><sup>10</sup></xref> Moreover, patients with PA suffer from more severe damage to target organs, such as the heart, brain and kidneys,<xref rid="R11" ref-type="bibr"><sup>11</sup></xref> highlighting the importance of early diagnosis and treatment of PA.</p><p>PCCs and PGLs are neuroendocrine tumours with hormonal secretion capabilities that originate from the adrenal medulla and the extra-adrenal sympathetic paraganglia, respectively, and are collectively referred to as pheochromocytoma and paraganglioma (PPGL). Clinically, PPGLs can manifest as episodes of hypertension, accompanied by a triad of headaches, palpitations and excessive sweating. However, clinical presentations can vary greatly, ranging from asymptomatic, mild episodic symptoms to severe life-threatening conditions.<xref rid="R12" ref-type="bibr"><sup>12</sup></xref> Diagnosis typically involves the detection of catecholamines in urine or plasma to screen for PCCs and PGLs.<xref rid="R13" ref-type="bibr"><sup>13</sup></xref> Currently, there are no precise data on the incidence or prevalence of PPGLs domestically. International reports indicate an incidence rate for PCC of 2&#8211;8 cases per million people per year, with a detection rate of 0.05%&#8211;0.1% for individuals not diagnosed during their lifetime at autopsy.<xref rid="R14" ref-type="bibr"><sup>14 15</sup></xref></p><p>CS, characterised by excessive cortisol secretion due to various causes, has an estimated annual incidence rate of 2&#8211;3 cases per million people and a prevalence rate of approximately 40 cases per million.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref> Excess cortisol can lead to centripetal obesity, moon face, polycythaemia, metabolic abnormalities, hypertension and other typical clinical characteristics. The overabundance of cortisol activates the renin&#8211;angiotensin&#8211;aldosterone system, enhancing the pressor response to vasoactive substances, increasing vasoconstriction, inhibiting vasodilation and acting on mineralocorticoid receptors, thereby often leading to elevated blood pressure. Additionally, cortisol affects the function of multiple systemic organs, reducing the body&#8217;s immunity.<xref rid="R17" ref-type="bibr"><sup>17</sup></xref> Patients with classic manifestations are very rare, and most exhibit only mild cortisol excess.<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> To reduce diagnostic delays and improve disease prognosis, it is crucial to develop simple and practical screening methods for high-risk populations.</p><p>Relying solely on the appearance of typical symptoms of the above diseases for evaluation often leads to irreversible damage and delays in optimal treatment timing.</p><p>Immunoassays, while convenient and accessible, suffer from poor specificity and precision, particularly because cortisol-like substances have very similar chemical structures, leading to significant interference from structurally similar compounds and background fluorescence. In the process of screening for endocrine hypertension, mass spectrometry, which is characterised by high sensitivity and high specificity, can significantly reduce the possibility of misdiagnosis. Recently, it has become a recommended technique in several consensus statements and guidelines.<xref rid="R19" ref-type="bibr"><sup>19 20</sup></xref></p><p>Therefore, screening for endocrine hypertension in hypertensive patients and adopting precise diagnostic and treatment approaches are key steps to improving hypertension management. Establishing standardised, sensitive and specific screening methods for endocrine hypertension is essential for prevention, early diagnosis and effective treatment.</p><p>However, large-scale, prospective epidemiological data on endocrine hypertension in the Chinese hypertensive population are still lacking. To address this gap, we designed a multicentre, prospective, real-world cohort study based on mass spectrometry technology. This study aims to (1) determine the prevalence and risk factors of endocrine hypertension; (2) establish standardised detection methods for aldosterone, catecholamines and cortisol; (3) explore efficient screening strategies for endocrine hypertension and (4) provide a scientific foundation for early identification, diagnosis, treatment, prognosis assessment and precision medicine in the management of endocrine hypertension.</p></sec><sec id="s2"><title>Method and analysis</title><sec id="s2-1"><title>Study design</title><p>This is a multicentre, prospective, real-world cohort study, aimed to investigate the epidemiological characteristics of endocrine hypertension resulting from PA, PPGLs and CS in Chinese people. In this study, we will collect data to calculate the prevalence of endocrine hypertension, identify risk factors, establish standardised screening methods for aldosterone, catecholamines and cortisol and investigate optimal cut-off values for different types of endocrine hypertension using mass spectrometry. The study will recruit patients with hypertension admitted to 116 designated hospitals across 16 provinces in China, including a range of tertiary and secondary hospitals. The full list of participating centres is provided in <xref rid="SP1" ref-type="supplementary-material">online supplemental file 1</xref>.</p><p>The study is planned to commence patient enrolment in April 2023, with an expected completion date for follow-up and final data collection in December 2026.</p></sec><sec id="s2-2"><title>Participants, inclusion and exclusion criteria</title><p>Eligible participants must meet all of the following criteria: age 18 years or older, provide informed consent, and meet one of the following conditions: (1) patients who are newly diagnosed with hypertension (according to the Chinese Guidelines for the Prevention and Treatment of Hypertension, 2018 revised edition) and have not received antihypertensive treatment, with clinic systolic blood pressure (SBP) &#8805;140&#8201;mm Hg and/or diastolic blood pressure (DBP) &#8805;90&#8201;mm Hg; (2) patients with well-controlled blood pressure who voluntarily agree to participate; (3) patients with refractory hypertension who have taken three antihypertensive drugs at tolerable and reasonable doses, including a thiazide diuretic, for at least 4 weeks and still have blood pressure values above the target level in the clinic and outside the clinic (including home blood pressure or ambulatory blood pressure monitoring) or patients who need at least four drugs to achieve blood pressure control and (4) patients with high-normal blood pressure, with clinic SBP 120&#8211;139&#8201;mmHg and/or DBP 80&#8211;89&#8201;mmHg, and have one of the following high-risk factors: overweight, obesity, alcohol consumption, abnormal blood glucose and abnormal triglycerides. In addition to the primary adult population, selected participating centres with paediatric capabilities may include adolescent hypertensive patients aged 12&#8211;17 years for predefined exploratory subgroup analyses. Inclusion of this subgroup is subject to separate ethics approval at those sites. The exclusion criteria are as follows: (1) severe hepatic dysfunction, congenital heart disease, malignancy or severe infection; (2) severe mental illness or cognitive impairment and (3) difficulty following up or inability to provide informed consent.</p></sec><sec id="s2-3"><title>Sample size estimation</title><p>To ensure the statistical power of our study, we conducted a priori sample size calculation. According to previous studies, the prevalence of hypertension is 23.2%,<xref rid="R21" ref-type="bibr"><sup>21</sup></xref> and endocrine hypertension accounts for approximately 5%&#8211;10% of hypertension cases.<xref rid="R9" ref-type="bibr"><sup>9 22 23</sup></xref> We anticipate a prevalence rate of 7% for the primary outcome in the population of interest, with a desired statistical power of 80% to detect this effect at a significance level of 0.05 (two-tailed) and a margin of error of 1%. It is estimated that at least 6000 patients will be enrolled in each participating centre. The anticipated sample size is 900&#8201;000 participants. This estimate was based on the maximum projected enrolment capacity across all participating centres at the time of study design.</p><p>The sample size is calculated via the following formula:</p><disp-formula id="eqnwl1"><mml:math id="M1" overflow="scroll"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:msubsup><mml:mi>&#956;</mml:mi><mml:mrow><mml:mi>&#945;</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mtext>&#160;</mml:mtext><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>&#961;</mml:mi><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>&#961;</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mstyle></mml:math></disp-formula></sec><sec id="s2-4"><title>Variables, outcomes and follow-ups</title><p>The participants will undergo a standardised baseline assessment including physical examinations, blood sampling and collection of demographic and clinical information. This includes age, sex, smoking status, previous medical history, family history of hypertension and medication. Both height and weight will be measured according to standard methods. Blood pressure will be measured by trained staff with an upper arm medical electronic sphygmomanometer after at least 5&#8201;min of rest. A total of three measurements will be taken with an interval of 1&#8201;min and the average value of the last two measurements will be recorded as office blood pressure.</p><p>Additionally, blood samples will be collected for the measurement of aldosterone, angiotensin I, renin activity, dopamine, epinephrine, norepinephrine, methoxyepinephrine, methoxynorepinephrine, vanillylmandelic acid, homovanillic acid, cortisol, 11-deoxycortisol, 21-deoxycortisol, corticosterone and cortisone. Based on the screening results of these biochemical markers, participants will be categorised into a general hypertensive population or the suspected endocrine hypertension population. For those suspected of having endocrine hypertension, further clinical diagnostic tests should be conducted to identify a confirmed endocrine hypertensive population. The diagnostic criteria for PA, PPGL and CS are detailed in <xref rid="SP2" ref-type="supplementary-material">online supplemental file 2</xref>.</p><p>The primary outcome of the study is to investigate the epidemiological characteristics of endocrine hypertension caused by PA, PPGL and CS among the Chinese hypertensive population.</p><p>The secondary outcomes include establishing standardised detection methods for aldosterone, catecholamines and cortisol based on mass spectrometry and developing efficient screening strategies for PA, PPGL and CS.</p><p>All participants will be followed for at least 1 year. Follow-up assessments include: blood pressure measurements at regular intervals; recording of antihypertensive treatment adjustments; evaluation of biochemical parameters where appropriate; documentation of new diagnoses of endocrine hypertension and recording of adverse events and major cardiovascular outcomes.</p></sec><sec id="s2-5"><title>Study implementation</title><p>A total of 116 participating centres across different provinces of China will be involved. Each centre will designate a principal investigator (PI) responsible for patient recruitment, data collection and protocol adherence. The coordinating centre will provide overall project management, quality control oversight and centralised laboratory analysis.</p><p>Eligible participants who meet the inclusion and exclusion criteria will be consecutively enrolled at each participating centre. After obtaining informed consent, baseline evaluations will be conducted, including demographic and clinical data collection, physical examination and laboratory testing.</p><p>Blood samples will be sent to the centralised laboratory for mass spectrometry-based screening for endocrine hypertension. Blood samples will undergo standardised pretreatment, including centrifugation to separate plasma, liquid-liquid extraction to remove interfering substances and nitrogen drying to concentrate the target analytes. Quantitative detection will be performed using liquid chromatography&#8211;tandem mass spectrometry (LC-MS/MS, Waters Xevo TQ-S micro or equivalent), following established protocols.</p><p>Participants with abnormal screening results will undergo further confirmatory diagnostic testing at their respective centres according to standardised protocols.</p><p>Based on screening and confirmatory test results, appropriate clinical management strategies will be implemented. All participants will be followed up for at least 1 year to monitor blood pressure, treatment outcomes and key clinical parameters.</p><p>The overall study workflow, organisational structure and quality control process are illustrated in <xref rid="F1" ref-type="fig">figure 1</xref>.</p><fig position="float" id="F1" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><title>Workflow of the study. CRF, case report form; CS, Cushing&#8217;s syndrome; PA, primary aldosteronism; PPGL, pheochromocytoma and paraganglioma.</title></caption><graphic position="float" orientation="portrait" xlink:href="bmjopen-15-8-g001.jpg"/></fig></sec><sec id="s2-6"><title>Quality control, data management and monitoring</title><p>Data will be entered into a pre-designed electronic data capture system with built-in logic checks to ensure data accuracy and completeness. All case report forms (CRFs) will be completed by trained investigators at each participating centre. The Chinese version of the CRF is provided in <xref rid="SP3" ref-type="supplementary-material">online supplemental file 3</xref>. Data entry will be performed by designated data managers, following the double data entry principle to minimise errors.</p><p>A hierarchical quality control system will be implemented. The PI of each participating centre is responsible for the initial quality control of their centre&#8217;s data. The coordinating centre will oversee overall data quality, consistency and protocol adherence. In addition, independent monitors will conduct regular external quality control assessments.</p><p>Monthly project meetings will be held to review recruitment progress, data quality and protocol compliance across all centres. Discrepancies or data quality issues identified during routine monitoring will be promptly addressed and rectified.</p></sec><sec id="s2-7"><title>Patient and public involvement</title><p>None.</p></sec><sec id="s2-8"><title>Statistical analyses</title><p>All statistical analyses will be performed using SPSS V.25 for Windows or R software (V.4.2.0 or higher). A two-sided p value of &lt;0.05&#8201;will be considered statistically significant. Descriptive statistics will be used to summarise baseline characteristics. Continuous variables will be presented as means&#177;SD or medians with IQRs, depending on their distribution. Categorical variables will be presented as frequencies and percentages. For group comparisons, Student&#8217;s t-test, Mann-Whitney U test or Kruskal-Wallis test will be applied for continuous variables, and Pearson&#8217;s &#967;<sup>2</sup> test or Fisher&#8217;s exact test for categorical variables, as appropriate. To identify risk factors associated with endocrine hypertension, univariate and multivariable logistic regression analyses will be conducted. Results will be presented as ORs with 95% CIs. The diagnostic performance of mass spectrometry-based screening for endocrine hypertension will be evaluated using receiver operating characteristic curve analysis, calculating sensitivity, specificity, positive predictive value and negative predictive value.</p><p>Subgroup analyses will be performed based on age, sex, blood pressure categories and centre level, where applicable. Multilevel modelling or generalised estimating equations will be considered to account for clustering effects in the multicentre design.</p></sec></sec><sec id="s3"><title>Ethics and dissemination</title><p>This study has been approved by the Medical Ethics Committee of Beijing Children&#8217;s Hospital ((2023)-E-028-Y) and all participating centres. Informed consent will be obtained from all participants or their legal representatives prior to enrolment. Results will be published in a peer-reviewed journal and presented at scientific meetings.</p></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>This study is the first large-scale, multicentre, prospective cohort designed to systematically screen for endocrine hypertension in China. Given the high prevalence, morbidity and mortality, early identification and aetiological diagnosis of secondary hypertension remain essential but under-addressed. Current screening practices for endocrine hypertension lack standardisation, which contributes to missed diagnoses and suboptimal hypertension control.</p><p>Our large-scale endocrine hypertension screening cohort study aims to fill the existing gap in epidemiological data on endocrine hypertension in China.</p><p>The main strengths of our study include the adoption of standardised screening protocols across 116 centres, the use of centralised laboratory testing and the incorporation of mass spectrometry as a sensitive and specific method for hormone detection. The large sample size and comprehensive clinical data collection will allow us to better characterise endocrine hypertension and its risk factors. In addition, the prospective design facilitates the development of risk prediction models to inform future screening strategies and management pathways.</p><p>Despite these strengths, the study has several limitations. Variability in medical expertise across centres may lead to diagnostic discrepancies. Moreover, confirmatory tests are only performed on patients who initially test positive for aldosteronism, potentially overestimating the efficiency of our screening process. Additionally, the completion rate of confirmatory tests might be low because of the diagnostic and treatment model at primary healthcare facilities and the time required for mass spectrometry sample analysis. This could lead to the loss of confirmatory test data when patients are referred to higher-level hospitals after initial positive screening, impacting the accuracy and completeness of the diagnostic data.</p><p>To mitigate these issues, we plan to hold monthly project meetings to synchronise and follow-up on enrolment and data entry at each centre. Regular communication and monitoring help identify and address problems promptly, ensuring the completeness and accuracy of the data.</p><p>In summary, this study is expected to provide valuable epidemiological data and methodological insights to guide future endocrine hypertension screening and management strategies in China.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supplementary material</title><supplementary-material id="SP1" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1136/bmjopen-2024-098446</object-id><label>online supplemental file 1</label><media xlink:href="bmjopen-15-8-s001.xlsx" id="d67e619" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SP2" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1136/bmjopen-2024-098446</object-id><label>online supplemental file 2</label><media xlink:href="bmjopen-15-8-s002.docx" id="d67e624" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SP3" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1136/bmjopen-2024-098446</object-id><label>online supplemental file 3</label><media xlink:href="bmjopen-15-8-s003.pdf" id="d67e629" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> This study is funded by the Development Center for Medical Science &amp; Technology National Health Commission of the People&#8217;s Republic of China and Zhejiang Biozon Medical Technology Co. The funding agency peer-reviewed and adjudicated the funding application and awarded funding for this study. The funding agency had no influence on the design, data collection, analysis, interpretation of data or results of this study, nor on the writing of this manuscript.</p></fn><fn fn-type="other"><p>Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<ext-link xlink:href="https://doi.org/10.1136/bmjopen-2024-098446" ext-link-type="uri">https://doi.org/10.1136/bmjopen-2024-098446</ext-link>).</p></fn><fn fn-type="other"><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn><fn fn-type="other"><p><bold>Patient consent for publication:</bold> Not applicable.</p></fn><fn fn-type="other"><p><bold>Collaborators:</bold> Screening for Endocrine Hypertension in China (SEHIC) Study: We extend our sincere gratitude to all the participating institutions and their researchers whose hard work and expertise were crucial to the success of this study. Special thanks to the following institutions and principal investigators:</p><p>Dr. Xingyu Wang, Beijing Hypertension League Institute; Dr Wenli Cheng, Beijing Anzhen Hospital of Capital Medical University; Dr Yuchun Zhu, West China Hospital of Sichuan University; Dr Jun Qian, Maanshan General Hospital of Ranger-Duree Healthcare; Dr Chengjing Xia, Shenzhen Guangming District People's Hospital; Dr Tong Zhang, Nanhai District People's Hospital of Foshan; Dr Heng Li, Dongguan Tungwah Hospital; Dr Chunping Zeng, The Fifth Affiliated Hospital of Guangzhou Medical University; Dr Zhihua Huang, Meizhou Hospital of Traditional Chinese Medicine; Dr Yequn Chen,The First Affiliated Hospital of Shantou University Medical College; Dr Songzhang Chen, Puning People's Hospital; Dr Weini Chen, Zhuhai Hospital of Integrative Medicine; Dr Yang Shen, Chaozhou People's Hospital; Dr Kang Chen, Zhongshan City People's Hospital; Dr Shenglong Yu, Guangzhou Panyu Central Hospital; Dr Guanxue Xu, The 5th Affiliated Hospital of Zunyi Medical University, Zhuhai; Dr Jilin Li, The Second Affiliated Hospital of Shantou University Medical College; Dr Yujing Ma,The First Affiliated Hospital of Henan University of Science and Technology; Dr Sha Ma, Luoyang Dongfang Peoples Hospital; Dr Hongxin Xu, Renmin Hospital of Wuhan University; Dr Congfei Zhu, Lianshui People's Hospital; Dr Ning Gu, Nanjing Hospital of Traditional Chinese Medicine; Dr Chen Wang, Jinhu County People's Hospital; Dr Shouyu Guo, The Second Affiliated Hospital of Nanjing Medical University; Dr Qin Yu, Affiliated Zhongshan Hospital of Dalian University; Dr Qian Chen, Shanghai Xuhui Central Hospital; Dr Xiaolei Jiang, Sichuan Mianyang 404 Hospital; Mianzhu People's Hospital; Dr Gang Li, Renshou County People's Hospital; Dr Zongze Yu, Guang'an People's Hospital; Dr Jianhua Lan, The Fourth People's Hospital of Zigong; Dr Guangqing Fu, Chengdu 363 Hospital of Aviation Industry of China; Dr Dan Zhu, Panzhihua Municipal Central Hospital; Dr Bing Bai, The Second People's Hospital of Liangshan Yi Autonomous Prefecture; Dr Bingxun He, Shehong Municipal Hospital of Traditional Chinese Medicine; Dr Dong Zhou, Pangang Group General Hospital; Dr Yong Wang, Ningbo First Hospital; Dr Chengwu Tang, The First People's Hospital of Huzhou; Dr Jie Yang, Zhejiang Xiaoshan Hospital; Dr Miaoyun Wang, The First People's Hospital of Lin'an District, Hangzhou City; Dr Linse Mei, Wenzhou Hospital of Traditional Chinese Medicine; Dr Qi Wu, People's Hospital, Beilun District, Ningbo City, Zhejiang Province; Dr Caizhen Qian, Zhuji People's Hospital; Dr Yong Li, Changxing People's Hospital; Dr Xinhong Zhou, Hangzhou Lin'an Traditional Chinese Medicine Hospital; Dr Shiwei Ye, The Second People&#8217;s Hospital of Lishui; Dr Hong Yuan, The First People's Hospital of Linping District, Hangzhou City; Dr Xiaojun Ji, Wenzhou Central Hospital; Dr Yingang Wu, Quzhou Second People's Hospital; Dr Xiaofeng Wu, Sanmen County People's Hospital; Dr Yiming Teng, Yiwu Central Hospital; Dr Bin Hu, Jiande First People's Hospital; Dr Zongyao Ai, Huzhou Hospital of Traditional Chinese Medicine; Dr Fujian Chen, Anji County People's Hospital; Dr Hao Lv, Quzhou Third Hospital; Dr Yang Fei, The First People's Hospital of Fuyang District, Hangzhou; Dr Xiaoshu Chen, Wenzhou People's Hospital; Dr Yu Hu, Cixi Longshan Hospital. We greatly appreciate the invaluable support provided by all these institutions and their researchers, whose contributions were essential to the successful completion of this study.We thank all the subjects for their participation. The authors are also grateful for the support provided by the Chinese government.</p></fn><fn fn-type="other"><p><bold>Patient and public involvement:</bold> Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewington</surname><given-names>S</given-names></name><name name-style="western"><surname>Lacey</surname><given-names>B</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>The Burden of Hypertension and Associated Risk for Cardiovascular Mortality in China</article-title><source>JAMA Intern Med</source><year>2016</year><volume>176</volume><fpage>524</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2016.0190</pub-id><pub-id pub-id-type="pmid">26975032</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mills</surname><given-names>KT</given-names></name><name name-style="western"><surname>Bundy</surname><given-names>JD</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>TN</given-names></name><etal>et al</etal></person-group><article-title>Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries</article-title><source>Circulation</source><year>2016</year><volume>134</volume><fpage>441</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.115.018912</pub-id><pub-id pub-id-type="pmid">27502908</pub-id><pub-id pub-id-type="pmcid">PMC4979614</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rimoldi</surname><given-names>SF</given-names></name><name name-style="western"><surname>Scherrer</surname><given-names>U</given-names></name><name name-style="western"><surname>Messerli</surname><given-names>FH</given-names></name></person-group><article-title>Secondary arterial hypertension: when, who, and how to screen?</article-title><source>Eur Heart J</source><year>2014</year><volume>35</volume><fpage>1245</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/eht534</pub-id><pub-id pub-id-type="pmid">24366917</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Funder</surname><given-names>JW</given-names></name><name name-style="western"><surname>Carey</surname><given-names>RM</given-names></name><name name-style="western"><surname>Mantero</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline</article-title><source>J Clin Endocrinol Metab</source><year>2016</year><volume>101</volume><fpage>1889</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1210/jc.2015-4061</pub-id><pub-id pub-id-type="pmid">26934393</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hung</surname><given-names>A</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>S</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Performance of the Aldosterone to Renin Ratio as a Screening Test for Primary Aldosteronism</article-title><source>J Clin Endocrinol Metab</source><year>2021</year><volume>106</volume><fpage>2423</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1210/clinem/dgab348</pub-id><pub-id pub-id-type="pmid">34008000</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montori</surname><given-names>VM</given-names></name><name name-style="western"><surname>Young</surname><given-names>WF</given-names></name></person-group><article-title>Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature</article-title><source>Endocrinol Metab Clin North Am</source><year>2002</year><volume>31</volume><fpage>619</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/s0889-8529(02)00013-0</pub-id><pub-id pub-id-type="pmid">12227124</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Omura</surname><given-names>M</given-names></name><name name-style="western"><surname>Saito</surname><given-names>J</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan</article-title><source>Hypertens Res</source><year>2004</year><volume>27</volume><fpage>193</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1291/hypres.27.193</pub-id><pub-id pub-id-type="pmid">15080378</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Funder</surname><given-names>J</given-names></name></person-group><article-title>Primary aldosteronism</article-title><source>Trends Cardiovasc Med</source><year>2022</year><volume>32</volume><fpage>228</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.tcm.2021.03.005</pub-id><pub-id pub-id-type="pmid">33775861</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monticone</surname><given-names>S</given-names></name><name name-style="western"><surname>Burrello</surname><given-names>J</given-names></name><name name-style="western"><surname>Tizzani</surname><given-names>D</given-names></name><etal>et al</etal></person-group><article-title>Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice</article-title><source>J Am Coll Cardiol</source><year>2017</year><volume>69</volume><fpage>1811</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2017.01.052</pub-id><pub-id pub-id-type="pmid">28385310</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Summary of the 2022 Report on Cardiovascular Health and Diseases in China</article-title><source><italic toggle="yes">Chin Med J</italic></source><year>2023</year><volume>136</volume><fpage>2899</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1097/CM9.0000000000002927</pub-id><pub-id pub-id-type="pmid">38018129</pub-id><pub-id pub-id-type="pmcid">PMC10752444</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monticone</surname><given-names>S</given-names></name><name name-style="western"><surname>D&#8217;Ascenzo</surname><given-names>F</given-names></name><name name-style="western"><surname>Moretti</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis</article-title><source>Lancet Diabetes Endocrinol</source><year>2018</year><volume>6</volume><fpage>41</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(17)30319-4</pub-id><pub-id pub-id-type="pmid">29129575</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Y-Hassan</surname><given-names>S</given-names></name><name name-style="western"><surname>Falhammar</surname><given-names>H</given-names></name></person-group><article-title>Cardiovascular Manifestations and Complications of Pheochromocytomas and Paragangliomas</article-title><source>J Clin Med</source><year>2020</year><volume>9</volume><elocation-id>2435</elocation-id><pub-id pub-id-type="doi">10.3390/jcm9082435</pub-id><pub-id pub-id-type="pmid">32751501</pub-id><pub-id pub-id-type="pmcid">PMC7465968</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lenders</surname><given-names>JWM</given-names></name><name name-style="western"><surname>Pacak</surname><given-names>K</given-names></name><name name-style="western"><surname>Walther</surname><given-names>MM</given-names></name><etal>et al</etal></person-group><article-title>Biochemical diagnosis of pheochromocytoma: which test is best?</article-title><source>JAMA</source><year>2002</year><volume>287</volume><fpage>1427</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1001/jama.287.11.1427</pub-id><pub-id pub-id-type="pmid">11903030</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stenstr&#246;m</surname><given-names>G</given-names></name><name name-style="western"><surname>Sv&#228;rdsudd</surname><given-names>K</given-names></name></person-group><article-title>Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data</article-title><source>Acta Med Scand</source><year>1958</year><volume>220</volume><fpage>225</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1111/j.0954-6820.1986.tb02755.x</pub-id><pub-id pub-id-type="pmid">3776697</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beard</surname><given-names>CM</given-names></name><name name-style="western"><surname>Sheps</surname><given-names>SG</given-names></name><name name-style="western"><surname>Kurland</surname><given-names>LT</given-names></name><etal>et al</etal></person-group><article-title>Occurrence of pheochromocytoma in Rochester</article-title><source>Mayo Clin Proc</source><year>1950</year><volume>58</volume><fpage>802</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">6645626</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lacroix</surname><given-names>A</given-names></name><name name-style="western"><surname>Feelders</surname><given-names>RA</given-names></name><name name-style="western"><surname>Stratakis</surname><given-names>CA</given-names></name><etal>et al</etal></person-group><article-title>Cushing&#8217;s syndrome</article-title><source>Lancet</source><year>2015</year><volume>386</volume><fpage>913</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)61375-1</pub-id><pub-id pub-id-type="pmid">26004339</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fleseriu</surname><given-names>M</given-names></name><name name-style="western"><surname>Auchus</surname><given-names>R</given-names></name><name name-style="western"><surname>Bancos</surname><given-names>I</given-names></name><etal>et al</etal></person-group><article-title>Consensus on diagnosis and management of Cushing&#8217;s disease: a guideline update</article-title><source>Lancet Diabetes Endocrinol</source><year>2021</year><volume>9</volume><fpage>847</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(21)00235-7</pub-id><pub-id pub-id-type="pmid">34687601</pub-id><pub-id pub-id-type="pmcid">PMC8743006</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teuber</surname><given-names>JP</given-names></name><name name-style="western"><surname>Nanba</surname><given-names>K</given-names></name><name name-style="western"><surname>Turcu</surname><given-names>AF</given-names></name><etal>et al</etal></person-group><article-title>Intratumoral steroid profiling of adrenal cortisol-producing adenomas by liquid chromatography- mass spectrometry</article-title><source>J Steroid Biochem Mol Biol</source><year>2021</year><volume>212</volume><elocation-id>S0960-0760(21)00117-5</elocation-id><pub-id pub-id-type="doi">10.1016/j.jsbmb.2021.105924</pub-id><pub-id pub-id-type="pmcid">PMC8734951</pub-id><pub-id pub-id-type="pmid">34089832</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mulatero</surname><given-names>P</given-names></name><name name-style="western"><surname>Monticone</surname><given-names>S</given-names></name><name name-style="western"><surname>Deinum</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension</article-title><source>J Hypertens</source><year>2020</year><volume>38</volume><fpage>1919</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1097/HJH.0000000000002510</pub-id><pub-id pub-id-type="pmid">32890264</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lagerstedt</surname><given-names>SA</given-names></name><name name-style="western"><surname>O&#8217;Kane</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Singh</surname><given-names>RJ</given-names></name></person-group><article-title>Measurement of plasma free metanephrine and normetanephrine by liquid chromatography-tandem mass spectrometry for diagnosis of pheochromocytoma</article-title><source>Clin Chem</source><year>2004</year><volume>50</volume><fpage>603</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2003.024703</pub-id><pub-id pub-id-type="pmid">14726465</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Status of Hypertension in China: Results From the China Hypertension Survey, 2012-2015</article-title><source>Circulation</source><year>2018</year><volume>137</volume><fpage>2344</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.032380</pub-id><pub-id pub-id-type="pmid">29449338</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossi</surname><given-names>GP</given-names></name><name name-style="western"><surname>Bernini</surname><given-names>G</given-names></name><name name-style="western"><surname>Caliumi</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients</article-title><source>J Am Coll Cardiol</source><year>2006</year><volume>48</volume><fpage>2293</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2006.07.059</pub-id><pub-id pub-id-type="pmid">17161262</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Primary Aldosteronism in Patients in China With Recently Detected Hypertension</article-title><source>J Am Coll Cardiol</source><year>2020</year><volume>75</volume><fpage>1913</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2020.02.052</pub-id><pub-id pub-id-type="pmid">32327102</pub-id></element-citation></ref></ref-list></back><sub-article id="sub-article1" article-type="aggregated-review-documents"><front-stub><title-group><article-title>Review Process File</article-title></title-group><pub-date pub-type="epub"><day>31</day><month>08</month><year>2025</year></pub-date></front-stub><body><fig id="d67e1256" position="anchor" orientation="portrait"><media xlink:href="bmjopen-2024-098446.reviewer_comments.pdf" position="float" orientation="portrait"/></fig></body></sub-article></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>